SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on March 20, 2003; DOI 10.1182/blood-2003-01-0110. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-01-0110v1 102/1/223    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Xin, K.-Q. Articles by Okuda, K. Search for Related Content PubMed PubMed Citation Articles by Xin, K.-Q. Articles by Okuda, K. Related Collections Immunobiology Immunotherapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 July 2003, Vol. 102, No. 1, pp. 223-228 IMMUNOBIOLOGY Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env Ke-Qin Xin, Yuka Hoshino, Yoshihiko Toda, Shizunobu Igimi, Yoshitsugu Kojima, Nao Jounai, Kenji Ohba, Akira Kushiro, Mayumi Kiwaki, Kenji Hamajima, Dennis Klinman, and Kenji Okuda From the Department of Bacteriology, Yokohama City University School of Medicine, Yokohama, Japan; Food and Drug Administration of National Health Institute, and Yakult Central Institute for Microbiological Research, Tokyo, Japan; Center for Biologics Evaluation and Research, and US Food and Drug Administration, Bethesda, MD. This study investigates whether genetically modified orally administered Lactococcus lactis (L lactis) could be used as an HIV vaccine. L lactis is immunogenic and extremely safe when delivered orally. We created a recombinant L lactis vector expressing the envelope protein of HIV on its cell surface. Oral immunization with this vector induced high levels of HIV-specific serum IgG and fecal IgA antibodies. Cell-mediated immune responses also were generated in both the regional lymph nodes and the spleen. Dendritic cells are readily infected by L lactis and appear to play a potential role in mediating the development of these immune responses. The protective efficacy of this vaccine strategy was demonstrated by challenging mice intraperitoneally with an HIV Env–expressing vaccinia virus. Their viral loads were 350-fold lower than those of control mice. These findings support the further development of L lactis–based HIV vaccines. (Blood. 2003; 102:223-228) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K.-Q. Xin, H. Mizukami, M. Urabe, Y. Toda, K. Shinoda, A. Yoshida, K. Oomura, Y. Kojima, M. Ichino, D. Klinman, et al. Induction of Robust Immune Responses against Human Immunodeficiency Virus Is Supported by the Inherent Tropism of Adeno-Associated Virus Type 5 for Dendritic Cells J. Virol., December 15, 2006; 80(24): 11899 - 11910. [Abstract] [Full Text] [PDF] J.-S. Lee, H. Poo, D. P. Han, S.-P. Hong, K. Kim, M. W. Cho, E. Kim, M.-H. Sung, and C.-J. Kim Mucosal Immunization with Surface-Displayed Severe Acute Respiratory Syndrome Coronavirus Spike Protein on Lactobacillus casei Induces Neutralizing Antibodies in Mice. J. Virol., April 1, 2006; 80(8): 4079 - 4087. [Abstract] [Full Text] [PDF] K. A. Aires, A. M. Cianciarullo, S. M. Carneiro, L. L. Villa, E. Boccardo, G. Perez-Martinez, I. Perez-Arellano, M. L. S. Oliveira, and P. L. Ho Production of Human Papillomavirus Type 16 L1 Virus-Like Particles by Recombinant Lactobacillus casei Cells Appl. Envir. Microbiol., January 1, 2006; 72(1): 745 - 752. [Abstract] [Full Text] [PDF] L. G. Bermudez-Humaran, N. G. Cortes-Perez, F. Lefevre, V. Guimaraes, S. Rabot, J. M. Alcocer-Gonzalez, J.-J. Gratadoux, C. Rodriguez-Padilla, R. S. Tamez-Guerra, G. Corthier, et al. A Novel Mucosal Vaccine Based on Live Lactococci Expressing E7 Antigen and IL-12 Induces Systemic and Mucosal Immune Responses and Protects Mice against Human Papillomavirus Type 16-Induced Tumors J. Immunol., December 1, 2005; 175(11): 7297 - 7302. [Abstract] [Full Text] [PDF] P. Mannam, K. F. Jones, and B. L. Geller Mucosal Vaccine Made from Live, Recombinant Lactococcus lactis Protects Mice against Pharyngeal Infection with Streptococcus pyogenes Infect. Immun., June 1, 2004; 72(6): 3444 - 3450. [Abstract] [Full Text] [PDF] K. Robinson, L. M. Chamberlain, M. C. Lopez, C. M. Rush, H. Marcotte, R. W. F. Le Page, and J. M. Wells Mucosal and Cellular Immune Responses Elicited by Recombinant Lactococcus lactis Strains Expressing Tetanus Toxin Fragment C Infect. Immun., May 1, 2004; 72(5): 2753 - 2761. [Abstract] [Full Text] [PDF] L. G. Bermudez-Humaran, N. G. Cortes-Perez, Y. Le Loir, J. M. Alcocer-Gonzalez, R. S. Tamez-Guerra, R. M. de Oca-Luna, and P. Langella An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci J. Med. Microbiol., May 1, 2004; 53(5): 427 - 433. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020